Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679561 | 0.86 | NPC1 (0.47) | NPC1RAB9AALDH1A1LMNACFTR | |
| SCHEMBL7959486 | 0.82 | NPC1 (0.52) | NPC1RAB9AALDH1A1LMNACFTR | |
| SCHEMBL16321456 | 0.78 | CYP11B2 (0.58) | ALDH1A1LMNAMAPTHTTHPGD | |
| SCHEMBL7975852 | 0.78 | PARP10 (0.42) | — | |
| SCHEMBL728745 | 0.78 | GSTP1 (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL9059926 | 0.77 | NCOA1 (0.45) | NPC1RAB9AALDH1A1BACE1MAOA | |
| SCHEMBL24924592 | 0.76 | CYP11B1 (0.45) | NPC1RAB9ALMNAMAPTHTT | |
| SCHEMBL5228519 | 0.76 | HTR2C (0.39) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27720413 | 0.75 | MT-CO2 (0.42) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL14102137 | 0.73 | CLK4 (0.45) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4173550-A | ORGANOLEPTIC | FIRMENICH SA (CH) | 1979-11-06 | — | — | US | claimed |
| US-4144200-A | 3-Phenyl-cyclopent-2-en-1-one in perfume compositions | FIRMENICH SA (CH) | 1979-03-13 | — | — | US | claimed |
| US-12509418-B2 | Chromophoric compounds and UV-absorbing compositions | LYGG CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250270164-A1 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | LYGG CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8785494-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO-PHARMA A/S (DK) | 2014-07-22 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5279999-A | Catalyst composition | SHELL OIL COMPANY (US) | 1994-01-18 | — | — | US | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0540108-A1 | Catalyst composition | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| US-4173550-A | ORGANOLEPTIC | FIRMENICH SA (CH) | 1979-11-06 | — | — | US | disclosed |
| US-4173550-A | ORGANOLEPTIC | FIRMENICH SA (CH) | 1979-11-06 | — | — | US | disclosed |
| US-4144200-A | 3-Phenyl-cyclopent-2-en-1-one in perfume compositions | FIRMENICH SA (CH) | 1979-03-13 | — | — | US | disclosed |
| US-4144200-A | 3-Phenyl-cyclopent-2-en-1-one in perfume compositions | FIRMENICH SA (CH) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270164-A1 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | ERCC1, TYR, ERCC5 | NPC1 1517/4885RAB9A 2211/4885ALDH1A1 1196/4885 |
| US-12509418-B2 | Chromophoric compounds and UV-absorbing compositions | LBR, ERCC1, MC1R | NPC1 968/4885RAB9A 2940/4885ALDH1A1 1591/4885 |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, NQO1, CBR3 | NPC1 1457/4885RAB9A 3893/4885ALDH1A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.